U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07627698) titled 'Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma' on May 31.
Brief Summary: This is a first-in-human, open-label, multicenter phase 1/2 study evaluating the safety, feasibility, recommended phase 2 dose (RP2D), and preliminary antitumor activity of allogeneic dual-target CSPG4/GD2 CAR-NK cells (EBDTKN-401) after lymphodepleting chemotherapy in adults with unresectable or metastatic cutaneous melanoma or metastatic uveal melanoma whose disease has progressed after standard therapy
Study Start Date: March 02
Study Type: INTERVENTIONAL
Condition:
Unresectable Melanoma
Metastatic Cutaneous Melanoma
Metastatic Uveal Melanoma
...